Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

08 January 2025: Articles  Japan

Radiological and Pathological Analysis of Pembrolizumab-Associated Lung Lesions: Diagnostic Challenges and Management

Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons

Tomohito Okano1BDEF, Hajime Fujimoto1ABC, Toshiyuki Ito1BDE, Atsushi Tomaru1BDE, Haruko Saiki1BDE, Tatsuki Tsuruga1ABE, Taro Yasuma23BCD, Corina N. D'Alessandro-Gabazza23CDE, Esteban C. Gabazza ORCID logo123DF*, Tetsu Kobayashi ORCID logo13ABDE

DOI: 10.12659/AJCR.945022

Am J Case Rep 2025; 26:e945022

0 Comments

Abstract

0:00

BACKGROUND: Pembrolizumab, a programmed cell-death protein-1 (PD-1)-targeting antibody, extends survival in cancer patients but may cause lung injury as a side effect. This immunotherapy enhances the immune system’s ability to recognize and eliminate cancer cells. However, its immunomodulatory action can sometimes lead to immune-related adverse events, including lung injury.

CASE REPORT: A 40-year-old female patient, previously managed for malignant melanoma of the left gluteal region with surgery and immune checkpoint inhibitors, was transitioned to pembrolizumab for ongoing cancer treatment. Subsequently, she was referred to our department for further evaluation due to findings on chest imaging revealing multiple nodules in the bilateral lung fields. The patient exhibited neither cough, fever, nor breathlessness. Bronchoscopic examination yielded no abnormalities. Cytological assessments were negative, as were cultures for bacteria, fungi, and acid-fast bacilli. Bronchoalveolar lavage and endobronchial ultrasound-guided transbronchial needle aspiration biopsy of the right lower lobe bronchus B9a were conducted. Pathological analysis identified a combination of acute inflammatory and chronic fibrotic lesions, primarily histiocytic, leading to a diagnosis of pembrolizumab-induced lung injury. Steroid pulse therapy followed by tapering resulted in improvement of the pulmonary shadows. The patient is currently under observation without requiring steroid therapy.

CONCLUSIONS: This case underscores the importance of vigilance for potential pembrolizumab-induced lung injury in patients undergoing immunotherapy for cancer treatment. Prompt recognition and appropriate management are essential for optimizing patient outcomes. Additionally, this case highlights the challenge of diagnosing lung lesions based solely on imaging, necessitating bronchoscopy with tissue sampling as a critical diagnostic tool.

Keywords: Melanoma, lung neoplasms, Tomography, X-Ray Computed

Introduction

Advanced-stage malignant melanoma presents significant therapeutic challenges and often carries a poor prognosis. Pembrolizumab, a humanized monoclonal antibody targeting the programmed cell-death protein 1 (PD-1) immune checkpoint, has shown efficacy in prolonging progression-free and overall survival in these patients [1]. Despite its benefits, pembrolizumab is associated with adverse effects, including drug-induced lung injury. Studies suggest that pembrolizumab monotherapy for malignant melanoma leads to drug-induced lung injury in approximately 1–3% of cases [2–5]. However, due to the rarity of this complication, its mechanisms are not fully understood, and definitive treatment protocols have yet to be established. Additionally, imaging results can vary significantly, and instances of pathologically confirmed diagnoses are uncommon.

In this report, we detail a case of pembrolizumab-induced lung injury distinguished by unique radiographic features. This case underscores the diagnostic complexities and the critical need for meticulous clinical evaluation to optimize patient outcomes. The discussion also aims to contribute to a deeper understanding of the pathological processes involved and to encourage the development of more effective management strategies for this serious complication.

Case Report

A 40-year-old woman with a previous diagnosis of left gluteal malignant melanoma was referred to our clinical department due to abnormal findings on chest radiography. The patient exhibited neither cough, fever, nor breathlessness at the time when the pathological pulmonary findings were identified. She had previously undergone surgery and received immune checkpoint inhibitors (nivolumab and ipilimumab) at the Department of Dermatology in our institution. During the course of nivolumab and ipilimumab therapy, she experienced severe hepatic injury (Grade 4) and developed type I diabetes mellitus (Grade 4). The diagnosis and treatment of liver injury were conducted by a hepatologist, whereas an endocrinologist from our medical institution managed the diagnosis and treatment of diabetes mellitus. The diagnoses of liver injury and diabetes mellitus were established based on criteria from international guidelines [6,7].

Subsequently, her treatment was switched to pembrolizumab, which she received for 31 courses. She had been diagnosed with dyslipidemia and had allergies to metals and adhesive bandages. The patient had no history of abnormal computed tomography (CT) findings or other diseases including interstitial lung disease or lung tumors. At the time of presentation to our clinic, she was being treated with atorvastatin, sitagliptin, and insulin. On presentation, her vital signs were stable, with a body temperature of 37.2°C, blood pressure of 114/72 mmHg, pulse of 108 beats/minute, oxygen saturation of 97% on room air, and a respiratory rate of 12 breaths/min. Physical examination was largely unremarkable, with no evidence of ocular or thyroid abnormalities, thoracic deformities, or hepatosplenomegaly. She had edema in the left lower leg secondary to lymph node dissection. Laboratory tests revealed elevated levels of surfactant protein A (SP-A), SP-D, and KL-6 (Table 1). The plain radiographs demonstrate bilateral patchy opacities, with a subtle reticulonodular pattern, more apparent in the lower lung zones (Figure 1). CT scans revealed multiple bilateral nodular opacities of varying sizes, predominantly peripheral in distribution. In addition to the nodules, there were areas of ground-glass opacity that were particularly noticeable in the lower lobes. These findings were accompanied by mild interlobular septal thickening (Figure 2). The bronchoscopic examination provided detailed visualization of the tracheal carina, as well as the bifurcation of the right upper and lower lobe bronchi, the right middle bronchus, and the segmental bronchi in the right lower lobe (B9 and B10) (Figure 3A–3D). Furthermore, an endobronchial ultrasound (EBUS) was utilized to facilitate accurate localization and biopsy of the nodule identified in the right lower lobe, ensuring precise sampling of the lesion (Figure 3E).

We considered several potential differential diagnoses, including drug-induced lung injury, metastatic lung tumor, multiple pulmonary infarctions, and infection. The total cell count of the bronchoalveolar lavage fluid was 2.3×105 cells/mL, with histiocytes comprising 32%, lymphocytes 58%, neutrophils 6%, and eosinophils 4%, indicating an elevated total cell count with lymphocytes predominating (Figure 4A). Histopathological examination of the lung biopsy specimens revealed chronic and acute inflammatory changes, with histiocytes being the predominant inflammatory cells and enlargement or swelling of the alveolar epithelial cells (Figure 4B, 4C). Cytological assessments, along with cultures for bacteria, fungi, and acid-fast bacilli, all yielded negative results. Furthermore, Pneumocystis jirovecii DNA polymerase chain reaction (PCR) testing on bronchoalveolar lavage fluid (BALF) was also negative. However, due to institutional protocols, routine DNA sequencing for pathogenic microorganisms in BALF was not performed, which limited our ability to conduct this specific analysis. Based on the bronchoalveolar lavage fluid and biopsy histological findings, the diagnosis of drug-induced lung injury (Common Terminology Criteria for Adverse Events, Grade 1) was suggested.

Pembrolizumab was implicated as the probable etiological agent. Pembrolizumab administration was ceased, and another chest CT scan was conducted 1 month later. The follow-up imaging revealed an expansion of the infiltrative shadow along the bronchovascular bundle, with certain areas demonstrating traction bronchiectasis (Figure 5A). Upon this finding, the patient was admitted, and steroid pulse therapy was initiated. The treatment course following steroid pulse administration is outlined in Figure 5B. Following steroid pulse therapy, the pulmonary opacities showed improvement (Figure 5A). Subsequently, a gradual tapering of the steroid dosage was commenced, culminating in the complete discontinuation of steroid therapy (Figure 5B). Since then, the patient has been under close observation without recurrence of either drug-induced lung injury or malignant melanoma.

Discussion

Malignant melanoma, arising from cancerous melanocytes, presents the highest mortality rate among skin cancers, posing a significant clinical challenge [8]. The global incidence of malignant melanoma exhibits substantial geographical variability, measured as new cases per 100 000 population [8]. The most affected regions include Australia/New Zealand, with Auckland, New Zealand, demonstrating the highest incidence rates for both men and women [9]. Conversely, Africa and Asia report considerably lower rates, with Japan averaging only 1 case per 100 000 individuals [10].

While the precise etiology of malignant melanoma remains elusive, ultraviolet (UV) radiation emerges as a key contributor to observed geographical disparities [11]. Sunlight emits 2 carcinogenic UV rays: UVA (315–400 nm) and UVB (280–315 nm). UVA, constituting 95% of sunlight’s UV rays, penetrates deeper into the dermis, whereas UVB induces more significant gene damage [12]. Interestingly, some melanomas develop independently of UV exposure, with germline mutations in CDKN2A implicated [13]. Additionally, BRAF V600E and NRAS mutations, present in 50% and 15% of melanomas, respectively, correlate with a more aggressive disease course, leading to the development of BRAF V600E-targeted therapies [13,14].

Immune checkpoint inhibitors have revolutionized oncology by empowering T cells to combat cancer cells through the inhibition of suppressive signals. Among these inhibitors, pembrolizumab, a humanized IgG monoclonal antibody targeting the PD-1 checkpoint, has shown efficacy in treating malignant melanoma [1,8]. Despite its success, treatment with anti-PD-1 antibodies, notably pembrolizumab, is linked to serious adverse effects, such as pneumonitis [15,16]. The incidence of this drug-induced condition often correlates with the presence of risk factors like chronic obstructive pulmonary disease (COPD), bronchial asthma, or prior chest radiotherapy [16–18]. Interestingly, our case showed none of these common predisposing factors. A meta-analysis has found that pneumonitis rates vary by the type of malignancy treated [15]. Notably, it occurs less frequently in malignant melanoma than in non-small cell lung cancer (NSCLC) or renal cell carcinoma [1,18,19]. The higher incidence in NSCLC patients can be attributed to underlying issues such as smoking, COPD, and interstitial lung disease [16,17,20]. However, the reasons for its high occurrence in renal cell carcinoma patients remain elusive.

Our current case developed pembrolizumab-associated pneumonitis. The incidence of pneumonitis induced by pembrolizumab is 5% in NSCLC patients and less than 1% in patients with malignant melanoma [1,18,19]. Due to its rarity, there is limited literature on this pathological condition, and the underlying mechanisms are not fully understood. Furthermore, standardized protocols for the management of pembrolizumab-induced lung injury are lacking. Cases of pneumonitis in patients with malignant melanoma treated with anti-PD-1 antibodies often show ground-glass opacities and infiltrative shadows in the lungs [21–26]. However, our present case exhibited previously unreported radiological features characterized by multiple nodular shadows in both lungs, making the diagnosis of lung abnormalities challenging. Initially, we considered metastatic lung tumors, pulmonary embolism, pulmonary mycosis, and pulmonary mycobacterial infection as differential diagnoses rather than drug-induced lung injury. A previous case reported by Arays et al also showed atypical lung radiological images for pneumonitis, necessitating a surgical lung biopsy to diagnose organizing pneumonia [27]. Among the 11 reported cases of pneumonitis induced by anti-PD-1/PD-L1 antibodies in malignant melanoma patients, only 4, including our present case, were pathologically diagnosed through transbronchial lung biopsy (TBLB) [21,23,27]. Therefore, while some cases omit bronchoscopy and surgical lung biopsy, tissue sampling remains essential for accurate diagnosis given the diverse potential causes. Our case underscores the importance of recognizing that atypical radiological findings of pneumonitis can occur in daily clinical practice and highlights the diagnostic value of TBLB in confirming drug-induced lung injury.

Conclusions

In summary, this case underscores the potential for pembrolizumab to cause lung injury in cancer patients. Despite its effectiveness in prolonging survival, clinicians must remain vigilant for respiratory complications. The patient’s positive response to steroid therapy and subsequent improvement emphasize the significance of early detection and management of pembrolizumab-related pulmonary adverse effects. Continuous monitoring is essential to ensure the patient’s sustained recovery without reliance on steroid therapy. Additionally, this case highlights the challenge of diagnosing lung lesions based solely on imaging, necessitating bronchoscopy with tissue sampling as a critical diagnostic tool.

Figures

Plain radiograph findings. Before the initiation of the 31st treatment cycle with pembrolizumab, anterior (A) and lateral (B) chest radiographs were performed. These images revealed bilaterally distributed infiltrates and nodular opacities, interspersed with areas of ground-glass opacity throughout the lung fields.Figure 1.. Plain radiograph findings. Before the initiation of the 31st treatment cycle with pembrolizumab, anterior (A) and lateral (B) chest radiographs were performed. These images revealed bilaterally distributed infiltrates and nodular opacities, interspersed with areas of ground-glass opacity throughout the lung fields. Lung CT scan findings. CT scans of the lungs, conducted with an axial slice thickness of 0.5 mm, were obtained before the initiation of the 31st course of pembrolizumab treatment. These scans revealed multiple infiltrating nodular shadows of varying sizes and some areas of ground-glass opacity, distributed bilaterally across the lung fields (A–D). A specific nodule, highlighted by a circled area, was selected for biopsy during the subsequent bronchoscopic procedure (D). CT, computed tomography.Figure 2.. Lung CT scan findings. CT scans of the lungs, conducted with an axial slice thickness of 0.5 mm, were obtained before the initiation of the 31st course of pembrolizumab treatment. These scans revealed multiple infiltrating nodular shadows of varying sizes and some areas of ground-glass opacity, distributed bilaterally across the lung fields (A–D). A specific nodule, highlighted by a circled area, was selected for biopsy during the subsequent bronchoscopic procedure (D). CT, computed tomography. Bronchoscopic findings. A bronchoscopic examination was conducted prior to the 31st course of pembrolizumab treatment. The bronchoscopic examination provided detailed images of the tracheal bifurcation (A), the bifurcation of the right upper and lower lobe bronchi (B), the right middle bronchus (C), and the segmental bronchi of the right lower lobe (B9 and B10) (D). Additionally, an endobronchial ultrasound (EBUS) was used to guide the biopsy of a nodule located in the right lower lobe (E), ensuring precise localization and sampling of the lesion.Figure 3.. Bronchoscopic findings. A bronchoscopic examination was conducted prior to the 31st course of pembrolizumab treatment. The bronchoscopic examination provided detailed images of the tracheal bifurcation (A), the bifurcation of the right upper and lower lobe bronchi (B), the right middle bronchus (C), and the segmental bronchi of the right lower lobe (B9 and B10) (D). Additionally, an endobronchial ultrasound (EBUS) was used to guide the biopsy of a nodule located in the right lower lobe (E), ensuring precise localization and sampling of the lesion. Bronchoalveolar lavage fluid cells and histopathological findings. Giemsa staining of bronchoalveolar lavage fluid cells at 400× magnification revealed a significantly elevated cell count, with the differential count predominantly showing histiocytes and lymphocytes (A). Hematoxylin and eosin staining of lung tissue sections demonstrated a complex inflammatory process characterized by both chronic and acute inflammation. The histopathology revealed a dense infiltration of histiocytes, coupled with pronounced swelling of the alveolar epithelial cells. Scale bars indicate 50 µm (B, C).Figure 4.. Bronchoalveolar lavage fluid cells and histopathological findings. Giemsa staining of bronchoalveolar lavage fluid cells at 400× magnification revealed a significantly elevated cell count, with the differential count predominantly showing histiocytes and lymphocytes (A). Hematoxylin and eosin staining of lung tissue sections demonstrated a complex inflammatory process characterized by both chronic and acute inflammation. The histopathology revealed a dense infiltration of histiocytes, coupled with pronounced swelling of the alveolar epithelial cells. Scale bars indicate 50 µm (B, C). Clinical course following treatment of lung injury. This figure presents serial CT scans alongside the clinical course of the patient. Day 1 corresponds to the initial patient visit. Day 46 presents data from a drug-free follow-up, providing insights into the patient’s condition without therapeutic intervention. Day 66 reflects data collected after the first course of steroid pulse therapy, highlighting the immediate therapeutic impact. Day 194 shows the patient’s status post-completion of prednisone therapy, offering a longer-term perspective on treatment efficacy. The CT scans were performed with an axial slice thickness of 0.5 mm. CT, computed tomography.Figure 5.. Clinical course following treatment of lung injury. This figure presents serial CT scans alongside the clinical course of the patient. Day 1 corresponds to the initial patient visit. Day 46 presents data from a drug-free follow-up, providing insights into the patient’s condition without therapeutic intervention. Day 66 reflects data collected after the first course of steroid pulse therapy, highlighting the immediate therapeutic impact. Day 194 shows the patient’s status post-completion of prednisone therapy, offering a longer-term perspective on treatment efficacy. The CT scans were performed with an axial slice thickness of 0.5 mm. CT, computed tomography.

References:

1.. Robert C, Schachter J, Long GV, Pembrolizumab versus ipilimumab in advanced melanoma.: N Engl J Med, 2015; 372(26); 2521-32

2.. Eggermont AMM, Blank CU, Mandala M, Adjuvant pembrolizumab versus placebo in resected stage III melanoma: N Engl J Med, 2018; 378(19); 1789-801

3.. Luke JJ, Rutkowski P, Queirolo P, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial: Lancet, 2022; 399(10336); 1718-29

4.. Ribas A, Puzanov I, Dummer R, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial: Lancet Oncol, 2015; 16(8); 908-18

5.. Robert C, Ribas A, Schachter J, Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study: Lancet Oncol, 2019; 20(9); 1239-51

6.. , 2. Diagnosis and classification of diabetes: Standards of care in diabetes – 2024.: Diabetes Care, 2024; 47(Suppl. 1); S20-S42

7.. Brennan PN, Cartlidge P, Manship T, Dillon JF, Guideline review: EASL clinical practice guidelines: Drug-induced liver injury (DILI).: Frontline Gastroenterol, 2022; 13(4); 332-36

8.. Arnold M, Singh D, Laversanne M, Global burden of cutaneous melanoma in 2020 and projections to 2040: JAMA Dermatol, 2022; 158(5); 495-503

9.. Jones WO, Harman CR, Ng AK, Shaw JH, Incidence of malignant melanoma in Auckland, New Zealand: Highest rates in the world: World J Surg, 1999; 23(7); 732-35

10.. Tomizuka T, Namikawa K, Higashi T, Characteristics of melanoma in Japan: A nationwide registry analysis 2011–2013: Melanoma Res, 2017; 27(5); 492-97

11.. Sample A, He YY, Mechanisms and prevention of UV-induced melanoma: Photodermatol Photoimmunol Photomed, 2018; 34(1); 13-24

12.. Borg A, Sandberg T, Nilsson K, High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families: J Natl Cancer Inst, 2000; 92(15); 1260-66

13.. Ellerhorst JA, Greene VR, Ekmekcioglu S, Clinical correlates of NRAS and BRAF mutations in primary human melanoma: Clin Cancer Res, 2011; 17(2); 229-35

14.. Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation: N Engl J Med, 2011; 364(26); 2507-16

15.. Nishino M, Giobbie-Hurder A, Hatabu H, Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis: JAMA Oncol, 2016; 2(12); 1607-16

16.. Toh CK, Wong EH, Lim WT, The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: A retrospective analysis: Chest, 2004; 126(6); 1750-56

17.. Bouros D, Hatzakis K, Labrakis H, Zeibecoglou K, Association of malignancy with diseases causing interstitial pulmonary changes: Chest, 2002; 121(4); 1278-89

18.. Garon EB, Rizvi NA, Hui R, Pembrolizumab for the treatment of non-small-cell lung cancer: N Engl J Med, 2015; 372(21); 2018-28

19.. Herbst RS, Baas P, Kim DW, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial: Lancet, 2016; 387(10027); 1540-50

20.. Coussens LM, Werb Z, Inflammation and cancer: Nature, 2002; 420(6917); 860-67

21.. Fiset PO, Shapera S, Butler MO, Tsao MS, Anti-PD-1-associated organizing pneumonia in a responding melanoma patient: Ann Oncol, 2016; 27(8); 1649-50

22.. Helber HA, Hada AL, Pio RB, Immunotherapy-induced pneumonitis: Cases report: Einstein (Sao Paulo), 2018; 16(2); eRC4030

23.. Kuint R, Lotem M, Neuman T, Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – a case report: Respir Med Case Rep, 2017; 20; 95-97

24.. Leroy V, Templier C, Faivre JB, Pembrolizumab-induced pneumonitis: ERJ Open Res, 2017; 3(2) 00081-2016

25.. Lu CS, Liu JH, Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports: Medicine (Baltimore), 2017; 96(1); e5747

26.. Rickard F, Hyams C, Low AT, Pneumonitis: A serious adverse effect of PD-L1 inhibitors including pembrolizumab: BMJ Case Rep, 2018; 2018 bcr2018224485

27.. Arays R, Wang P, A case of pembrolizumab-induced localized organizing pneumonia: Scand J Immunol, 2018; 88(1); e12677

Figures

Figure 1.. Plain radiograph findings. Before the initiation of the 31st treatment cycle with pembrolizumab, anterior (A) and lateral (B) chest radiographs were performed. These images revealed bilaterally distributed infiltrates and nodular opacities, interspersed with areas of ground-glass opacity throughout the lung fields.Figure 2.. Lung CT scan findings. CT scans of the lungs, conducted with an axial slice thickness of 0.5 mm, were obtained before the initiation of the 31st course of pembrolizumab treatment. These scans revealed multiple infiltrating nodular shadows of varying sizes and some areas of ground-glass opacity, distributed bilaterally across the lung fields (A–D). A specific nodule, highlighted by a circled area, was selected for biopsy during the subsequent bronchoscopic procedure (D). CT, computed tomography.Figure 3.. Bronchoscopic findings. A bronchoscopic examination was conducted prior to the 31st course of pembrolizumab treatment. The bronchoscopic examination provided detailed images of the tracheal bifurcation (A), the bifurcation of the right upper and lower lobe bronchi (B), the right middle bronchus (C), and the segmental bronchi of the right lower lobe (B9 and B10) (D). Additionally, an endobronchial ultrasound (EBUS) was used to guide the biopsy of a nodule located in the right lower lobe (E), ensuring precise localization and sampling of the lesion.Figure 4.. Bronchoalveolar lavage fluid cells and histopathological findings. Giemsa staining of bronchoalveolar lavage fluid cells at 400× magnification revealed a significantly elevated cell count, with the differential count predominantly showing histiocytes and lymphocytes (A). Hematoxylin and eosin staining of lung tissue sections demonstrated a complex inflammatory process characterized by both chronic and acute inflammation. The histopathology revealed a dense infiltration of histiocytes, coupled with pronounced swelling of the alveolar epithelial cells. Scale bars indicate 50 µm (B, C).Figure 5.. Clinical course following treatment of lung injury. This figure presents serial CT scans alongside the clinical course of the patient. Day 1 corresponds to the initial patient visit. Day 46 presents data from a drug-free follow-up, providing insights into the patient’s condition without therapeutic intervention. Day 66 reflects data collected after the first course of steroid pulse therapy, highlighting the immediate therapeutic impact. Day 194 shows the patient’s status post-completion of prednisone therapy, offering a longer-term perspective on treatment efficacy. The CT scans were performed with an axial slice thickness of 0.5 mm. CT, computed tomography.

In Press

Case report  China

Neonatal Familiar Cleidocranial Dysplasia: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.946322  

Case report  Japan

Acute Extensor Pollicis Longus Tendon Injury Associated with a Distal Radius Fracture: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.946399  

Case report  China

Severe Neonatal Asphyxia Associated with Ureaplasma urealyticum Infection: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.946249  

Case report  Malaysia

Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent

Am J Case Rep In Press; DOI: 10.12659/AJCR.945579  

Most Viewed Current Articles

21 Jun 2024 : Case report  China (mainland) 82,657

Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...

DOI :10.12659/AJCR.944371

Am J Case Rep 2024; 25:e944371

0:00

07 Mar 2024 : Case report  USA 49,061

Neurocysticercosis Presenting as Migraine in the United States

DOI :10.12659/AJCR.943133

Am J Case Rep 2024; 25:e943133

0:00

20 Nov 2023 : Case report  Saudi Arabia 23,527

Azithromycin Treatment for Acne Vulgaris: A Case Report on the Risk of Clostridioides difficile Infection

DOI :10.12659/AJCR.941424

Am J Case Rep 2023; 24:e941424

0:00

18 Feb 2024 : Case report  Japan 22,089

A Case of Thoracic Empyema Caused by Actinomyces naeslundii

DOI :10.12659/AJCR.943030

Am J Case Rep 2024; 25:e943030

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923